Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy

Cantin, Jacques; Scarth, Hugh; Levine, Mark; Hugi, Maria
July 2001
CMAJ: Canadian Medical Association Journal;7/24/2001, Vol. 165 Issue 2, p166
Academic Journal
Completion date: Apr. 9, 2001.


Related Articles

  • Biopsy battle favours SLNB.  // PharmacoEconomics & Outcomes News;1/23/2010, Issue 595, p10 

    The article discusses research on the cost and impact of sentinel lymph node biopsy on pain and quality of life of breast cancer patients compared with complete lymphadenectomy, that references a study by J.-M. Classe and colleagues presented in the 32nd Annual San Antonio Breast Cancer...

  • Sentinel Lymph Node Biopsy in Patients with Breast Cancer. Sadovsky, Richard // American Family Physician;01/15/2000, Vol. 61 Issue 2, p503 

    Deals with a study by S.S. Bass and associates which evaluated the effectiveness of lymphatic mapping and sentinel lymph node biopsy in the surgical treatment of patients with breast cancer. Methods of identifying the appropriate lymph node; Number of patients with breast cancer that...

  • Should we look to the sentinel node?  // Cortlandt Forum;11/25/99, Vol. 12 Issue 11, p123 

    Focuses on the use of sentinel lymph node (SLN) biopsy as an alternative to axillary lymph node dissection (ALND) for breast cancer. Postoperative complications of ALND; Methods to identify SLN; Key considerations before using SLN biopsy as replacement of ALND.

  • Sentinel Lymph Node Biopsy and Axillary Dissection in Breast Cancer: Results in a Large Series. Veronesi, Umberto; Paganelli, Giovanni; Viale, Giuseppe; Galimberti, Viviana; Luini, Alberto; Zurrida, Stefano; Robertson, Chris; Sacchini, Virgilio; Veronesi, Paolo; Orvieto, Enrico; De Cicco, Concetta; Intra, Mattia; Tosi, Giampiero; Scarpa, Daniela // JNCI: Journal of the National Cancer Institute;02/17/99, Vol. 91 Issue 4, p368 

    Provides information on a study which attempted to clarify the role of sentinel lymph node biopsy in the clinical management of breast cancer. Patients and methods; Results and discussion.

  • Breast cancer treatments becoming less invasive. Yazdi, G. Paul // South County Journal;9/19/2012, Vol. 47 Issue 38, pB2 

    The article offers information on available breast cancer treatments that are becoming less invasive including lumpectomy which removes only the cancer and surrounding margin of normal breast tissue, and sentinel lymph node biopsy which removes only the affected lymph nodes.

  • Use of the dye-guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection. TOMOKO TAKAMARU; GORO KUTOMI; FUKINO SATOMI; HIROAKI SHIMA; KEISUKE OHNO; HIDEKAZU KAMESHIMA; YASUYO SUZUKI; TOUSEI OHMURA; HIROYUKI TAKAMARU; MASANORI NOJIMA; MITSURU MORI; KOICHI HIRATA // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 2, p456 

    For sentinel lymph node biopsy (SLNB), a combination of dye-guided and γ-probe-guided methods is the most commonly used technique. However, the number of institutes in which the γ-probe-guided method is able to be performed is limited, since special equipment is required for the method. In...

  • CLINICAL AND PATHOLOGIC FEATURES ASSOCIATED WITH REMOVAL OF FEWER THAN 10 LYMPH NODES IN AXILLARY LYMPH NODE DISSECTION FOR BREAST CANCER. Ünal, Bülent; Polat, Ayfer Kamalı; Andaçoğlu, Oya; Bonaventura, Marguerite; Gür, Serhat; Soran, Atilla // Meme Sagligi Dergisi / Journal of Breast Health;2011, Vol. 7 Issue 4, p221 

    Background: Current guidelines suggest that when performing axillary lymph node dissection for treatment of breast cancer, a minimum of 10 lymph nodes should be removed to allow for accurate pathologic staging to guide the treatment decision regarding the adjuvant treatment. The purpose of this...

  • Sentinal node biopsy a staging policy, not a tx.  // Dermatology Times;May2004, Vol. 25 Issue 5, p63 

    Presents a study on the identification of malignant melanoma by using a sentinal node biopsy according to research from Florida. Consideration of elective loan and oburator lymph node dissection; Performance of curative surgery; Identification of Level One evidence on results from well-designed...

  • S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. Yong Wha Moon; Soohyeon Lee; Byeong-Woo Park; Eun-Kyung Kim; Seung Il Kim; Ja Seung Koo; Seho Park; Min Jung Kim; Hyun Cheol Chung; Joo-Hang Kim; Joohyuk Sohn; Moon, Yong Wha; Lee, Soohyeon; Park, Byeong-Woo; Kim, Eun-Kyung; Kim, Seung Il; Koo, Ja Seung; Park, Seho; Kim, Min Jung; Chung, Hyun Cheol // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.Methods: Patients received AC every 3 weeks...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics